Which public route, batch label, seller, laboratory name, date, and displayed result fields were visible when this dataset was refreshed.
Public batch-report evidenceSemaglutide
Semaglutide
COA trail.
Review 9 public Semaglutide COA and lab-report routes across 1 seller index and 3 named laboratories, with batches, dates, displayed results, and original sources.
Direct answer
Where can you inspect public Semaglutide reports?
This release links 9 public report routes across 1 seller index and 3 named laboratories. Every route below preserves the displayed batch, variant, date type, result fields, and original source.
Who selected the sample, whether it represents inventory, whether custody was controlled, and whether a later supplied vial shares the tested sample's identity or contents.
Field coverage
See what the index exposes before opening every file.
Coverage is the share of these 9 seller-index rows with a transcribed value. It measures index visibility, not test completeness or a pass rate.
Batch or lot
100%9 of 9 records
Named laboratory
100%9 of 9 records
Displayed date
100%9 of 9 records
Quantity value
0%0 of 9 records
Purity value
100%9 of 9 records
Endotoxin field
56%5 of 9 records
Verification key
67%6 of 9 records
Source map
Who published the route, and which lab name appears?
Counts describe this bounded public index. A named laboratory does not establish accreditation scope, sampling independence, chain of custody, or inventory representation.
Seller indexes
Prime Peptides
9
Named laboratories
Janoshik Laboratories
6
Accumark Labs
2
Vanguard Laboratory
1
Routes hosted on a laboratory verification domain.
Files hosted by the seller or its public storage route.
Rows where the seller index exposed a quantity result.
Rows where the seller index exposed a purity result.
Complete register
9 public routes, with the missing fields left visible.
Rows are ordered by the displayed analysis date or seller index date. Open the original route for methods, signatures, report identifiers, acceptance criteria, and any fields not exposed by the source index.
| Date shown | Batch or lot | Variant | Seller | Named lab | Displayed results | Document |
|---|---|---|---|---|---|---|
| Apr 28, 2026Analysis date | 2242026SM | Semaglutide Teal CapNo price board | Prime Peptides | Janoshik Laboratories | Purity 99.172%Endotoxin Pass | Open report E15NW2FS54XA |
| Apr 28, 2026Analysis date | 3022026SM | Semaglutide Blue CapNo price board | Prime Peptides | Janoshik Laboratories | Purity 99.862%Endotoxin Pass | Open report YE1LHF4GKZEW |
| Apr 28, 2026Analysis date | 3142026SM | Semaglutide White CapNo price board | Prime Peptides | Janoshik Laboratories | Purity 99.751%Endotoxin Pass | Open report 8LXRRQF586XL |
| Apr 10, 2026Analysis date | 3272026SM | Semaglutide 5mgNo price board | Prime Peptides | Janoshik Laboratories | Purity 99.681% | Open report 543Q35ECX47Y |
| Mar 31, 2026Analysis date | 2182026SM | Semaglutide 5mgNo price board | Prime Peptides | Accumark Labs | Purity 99.41% | Open report |
| Mar 31, 2026Analysis date | 2182026SM | Semaglutide 5mgNo price board | Prime Peptides | Accumark Labs | Purity 99.41%Endotoxin Pass | Open report |
| Mar 25, 2026Analysis date | 2122026SM | Semaglutide 5 (Green Lid)No price board | Prime Peptides | Vanguard Laboratory | Purity 99.02%Endotoxin Pass | Open report |
| Feb 16, 2026Analysis date | 1052026SM | Semaglutide 10mgNo price board | Prime Peptides | Janoshik Laboratories | Purity 99.524% | Open report N9MVUV24BVJA |
| Jan 22, 2026Analysis date | 11092025SM | Semaglutide 15mgNo price board | Prime Peptides | Janoshik Laboratories | Purity 99.791% | Open report M55FRN4QFTU8 |
Identity and custody boundary
A seller-labelled research item is not established as an FDA-approved semaglutide medicine or as part of an authorized medicine supply chain.
Direct answers
Semaglutide report questions, answered from the fields.
Where can I find public Semaglutide COAs and lab reports?
This page links 9 public Semaglutide report routes observed across 1 seller indexes. Each row preserves the displayed batch or lot, variant, named laboratory, date label, available result fields, direct document route, and seller index.
How many Semaglutide batch reports are in this index?
The current release contains 9 report routes representing 8 displayed batch or lot identifiers and 3 normalized laboratory names. This is a bounded public-source count, not a count of all reports or current inventory batches in the market.
Does a high purity percentage prove that Semaglutide is safe or authentic?
No. A displayed purity result does not by itself prove compound identity, labelled quantity, sterility, endotoxin status, sample custody, inventory representation, authenticity, safety, legality, or suitability for use. Read the full document and keep each evidence field separate.
Why are some dates labelled seller index dates?
A seller index date is the date attached to the public report entry when the index did not expose a separate analysis date in the fields transcribed for this release. Of the 9 routes here, 9 display an analysis date in the source index. Open the document for its complete date fields.
What does a missing result mean in this report trail?
It means the seller index did not expose that value in the fields transcribed into this release. It does not prove that the underlying document omits the test, and it does not permit a pass or fail inference. Open the original report before interpreting a blank field.
Method and next checks
Use the route. Do not borrow certainty from it.
This page is generated only for products with at least three public document routes in the current ledger. It preserves source-index wording and explicitly labels missing values. It does not score sellers, average incompatible methods, or convert a report into a safety or product-quality verdict.
Suggested citation: Peptide Local Editorial Desk. “Semaglutide Public COA and Laboratory Report Trail.” Version 2026-07-21. Peptide Local.
Open source index ↗Search the complete 101-report ledger →Run the ten-field COA audit →Open Semaglutide identity and evidence context →